Electrochemotherapy (ECT) has emerged as a complementary treatment for superficial metastases. Fifty-two consecutive patients with different cancer histotypes, mainly melanoma and breast cancer, with disease unsuitable for conventional treatments underwent bleomycin-based ECT for cutaneous and subcutaneous metastases. Toxicity, local response, response duration, and the impact on quality of life were evaluated. A total of 608 tumor nodules were treated (mean, 12 per patient), with 27% of patients affected by nodules >3 cm in size. Treatment was tolerated well, especially under general sedation. An objective response was obtained in 50 (96%) of 52 patients 1 month after the first application. Twenty-two patients underwent a second treatment (because of partial response or the appearance of new lesions). Partial response at first ECT achieved a response consolidation at second application: 80% complete response, 20% partial response. Some patients underwent up to five treatments because of new lesions, but maintained superficial tumor control. After a mean follow-up of 9 (range, 2–21) months, only two patients experienced relapse in the treatment field. Through a nonvalidated eight-item questionnaire (assessing wound healing and bleeding, aesthetic impairment, daily activities, social relations, pain, treatment satisfaction, acceptance of retreatment), most patients reported a benefit in local disease-related complaints and in activity of daily living. In a palliative setting, ECT proved to be safe, effective in all tumors treated, and useful in preserving patients’ quality of life. This benefit, although preliminary, deserves further assessment after a formal validation of the dedicated questionnaire.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
We thank the nursing staff members of CE.MU.R.N.I. (Centro Multidisciplinare Radiazioni Non Ionizzanti) and of the Melanoma Center at the Istituto Oncologico Veneto (IOV), Padova, for their assistance with patient care.
Chen C, Smye SW, Robinson MP, et al. Membrane electroporation theories: a review. Med Biol Eng Comput. 2006;44:5–14.CrossRefPubMedGoogle Scholar
Somiari S, Glasspool-Malone J, Drabick JJ, et al. Theory and in vivo application of electroporative gene delivery. Mol Ther. 2000;3:178–87.CrossRefGoogle Scholar
Heller R, Jaroszeski MJ, Atkin A, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett. 1996;389:225–8.CrossRefPubMedGoogle Scholar
Cemazar M, Sersa G. Electrotransfer of therapeutic molecules into tissues. Curr Opin Mol Ther. 2007;9:554–62.PubMedGoogle Scholar
Mossop BJ, Barr RC, Henshaw W, et al. Electric fields in tumors exposed to external voltage sources: implication for electric field-mediated drug and gene delivery. Ann Biochem Eng. 2006;34:1564–72.CrossRefGoogle Scholar
Mir LM. Terapeutic perspectives of in vivo cell electropermeabilization. Bioelecrtochemistry. 2000;53:1–10.CrossRefGoogle Scholar
Belehradek M, Domenge C, Luboinski B, et al. Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial. Cancer. 1993;72:3694–700.CrossRefPubMedGoogle Scholar
Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv Drug Del Rev. 1999;35:107–18.CrossRefGoogle Scholar
Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 2003;29:371–87.CrossRefPubMedGoogle Scholar
Serša G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical use. EJC Suppl. 2006;4:52–9.Google Scholar
Mir LM, Gehl J, Sersa G, et al. Standard operating procedures of the Electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator by means of invasive or non-invasive electrodes. EJC Suppl. 2006;4:14–25.CrossRefGoogle Scholar
Marty M, Serša G, Garbay JR, et al. Electrochemotherapy—An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE study. EJC Suppl. 2006;4:3–13.CrossRefGoogle Scholar
Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMedGoogle Scholar
Rols MP, Bachaud JM, Giraud P, et al. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res. 2000;10:468–74.CrossRefPubMedGoogle Scholar
Giardino R, Fini M, Bonazzi V, et al. Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. Biomed Pharmacol. 2006;60:458–62.CrossRefGoogle Scholar
Garbay JR, Billard V, Bernat C, et al. Successful repetitive treatments by Electrochemotherapy of multiple unresectable Kaposi sarcoma nodules. EJC Suppl. 2006;4:29–31.CrossRefGoogle Scholar
Whelan MC, Larkin JO, Collins CG, et al. Effective treatment of an extensive recurrent breast cancer which was refractory to multimodal therapy by multiple applications of Electrochemotherapy. EJC Suppl. 2006;4:32–4.CrossRefGoogle Scholar
Colombo GL, Di Matteo S, Mir LM. Cost-effectiveness of Electrochemotherapy with the Cliniporator vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag. 2008;4:1–8.Google Scholar
Byrne MC, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 2005;15:45–51.CrossRefPubMedGoogle Scholar
Gaudy C, Richard MA, Folchetti G, et al. Randomized controlled study of Electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg. 2006, 10:115–21.CrossRefPubMedGoogle Scholar
Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008;15:2215–22.CrossRefPubMedGoogle Scholar
Domenge C, Orlowski S, Luboinski B, et al. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer. 1996;77:956–63.CrossRefPubMedGoogle Scholar
Gilbert RA, Jaroszeski MJ, Heller R. Novel electrode designs for electrochemotherapy. Biochim Biophys Acta. 1997;1334:9–14.CrossRefPubMedGoogle Scholar
Heller L, Pottinger C, Jaroszeski MJ, et al. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunità. Melanoma Res. 2000;10:577–83.CrossRefPubMedGoogle Scholar
Roux S, Bernat C, Al-Sakere B, et al. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother. 2008;57:1291–300.CrossRefPubMedGoogle Scholar
Serša G, Kranjc S, Čemažar M, et al. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys. 2000;46:1037–41.CrossRefPubMedGoogle Scholar
Serša G, Štabuc B, Čemažar M, et al. Electrochemotherapy with cisplatin: the systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res. 2000, 10:381–5.CrossRefPubMedGoogle Scholar
Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.CrossRefPubMedGoogle Scholar
Wagner LI, Wenzel L, Shaw E, et al. Patient-reported outcomes in Phase II cancer clinical trials: lesson learned and future directions. J Clin Oncol. 2007;25:5058–62.CrossRefPubMedGoogle Scholar